Download PDF
Hamostaseologie 1999; 19(03): 108-111
DOI: 10.1055/s-0038-1660391
Übersichts- und Originalarbeiten/Review and Original Articles
Schattauer GmbH

Effects of Glycoprotein IIb/IIIa Inhibitors on Platelet Function

S. Harder
1   Institute of Clinical Pharmacology of the J. W. Goethe University, Frankfurt a.M.
,
C. M. Kirchmaier
2   Deutsche Klinik für Diagnostik, Wiesbaden
,
H. K. Breddin
3   International Institute of Thrombosis and Vascular Diseases, Frankfurt a. M., Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
27 June 2018 (online)

Also available at
    Permissions and Reprints

Summary

We have studied the effect of two monoclonal antibodies against the G PI Ib/IIIa-receptor (abciximab and YM 337) on different platelet functions in healthy male volunteers. Platelet aggregation (1, 5 and 20 μM ADP), platelet adhesion, fibrinogen binding, bleeding time and platelet induced thrombin generation (PITT) were studied after an i.v. bolus of different doses of YM337 and after a bolus (0.35 mg/kg) plus 6 h infusion at different dose levels of YM337 or after a bolus of 0.25 mg/kg abciximab followed by a six hour infusion of 0,125 μg/kg/min. After 0.2 mg/kg and 0.4 mg/kg bolus of YM337 fibrinogen binding was reduced by >80%, coinciding with a prolongation of bleeding time to approx. 60 min. Platelet aggregation returned to normal within 24 h and adhesion within 48 h. Bleeding times returned to normal already 4 h after cessation of the infusion. YM337 and abciximab effectively inhibit GPIIb/IIIa mediated platelet aggregation and adhesion in volunteers. In parallel, platelet induced thrombin generation is markedly reduced. The best method to monitor treatment with GPIIb/IIIa inhibitors still has to be defined.

Keywords

Platelet aggregation inhibitors - antibodies - GPIIb/IIIa - YM337 - abciximab
 

  • References

  • 1 Coller B.S. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest 1997; 100 (Suppl. 11) S57-60.
    PubMedGoogle Scholar
  • 2 Tcheng J.E, Ellis S.G, George B.S, Kereiakes D.J, Kleiman N.S, Talley J.D, Wang A.L, Weisman H.F, Califf R.M, Topol E.J. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody FAB 7E3 in high-risk coronary angioplasty. Circulation 1994; 90: 1757-64.
    CrossrefPubMedGoogle Scholar
  • 3 Harder S, Kirchmaier C.M, Krzywanek H.J, Westrup D, Bae J.W, Breddin H.K. Pharmacokinetics and pharmacodynamic effects of a new antibody glycoprotein IIb/IIIa inhibitor (YM337) in healthy subjects. Circulation 1999,100:in press.
    PubMedGoogle Scholar
  • 4 Born G.V.R. Quantitative investigations into the aggregation of blood platelets. J Phys 1962; 162: 67-8.
    PubMedGoogle Scholar
  • 5 Breddin H.K, Ziemen M, Bauer O, Harmann W, Schaudinn L, Schlosser V, Winterhagen A, Krzywanek H.J. Time and temperature dependent changes of ADP and collagen induced and spontaneous’ aggregation. Thrombosis Res 1980; 19: 621-38.
    CrossrefPubMedGoogle Scholar
  • 6 Faraday N, Goldschmidt-Clermont P, Dise K, Bray P.F. Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry. J Lab Clin Med 1994; 123: 728-40.
    PubMedGoogle Scholar
  • 7 Breddin K. Zur Messung der Thrombo-zytenadhäsivität. Thromb Diath Haemorrh 1964; 12: 269-80.
    PubMedGoogle Scholar
  • 8 Basic-Micic M, Roman C, Herpel U, Kling E, Scholz B, Breddin H.K. Platelet-induced thrombin generation time: A new sensitive global assay for platelet function and coagulation. Haemostasis 1992; 22: 309-21.
    PubMedGoogle Scholar
  • 9 Mascelli M.A, Worley S, Veriabo N.J, Lance E.T, Mack S, Schaible T, Weisman H.F, Jordan R.E. Rapid assessment of platelet function with a modified whole-blood aggre-gometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy. Circulation 1997; 38: 60-6.
    PubMedGoogle Scholar
  • 10 Harrington R.A, Kleiman N.S, Kottke-Marchant K, Lincoff A.M, Tcheng J.E, Sigmon K.N, Joseph D, Rios G, Trainor K, Rose D. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995; 76: 1222-7.
    CrossrefPubMedGoogle Scholar
  • 11 Meyer M, Kirchmaier C.M, Schirmer A, Spangenberg P, Strohl C, Breddin H.K. Aquired disorder of platelet function associated with autoantibodies against glycoprotein IIb-IIIa complex. Thromb Haemost 1991; 65: 491-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Hagcndorff K.B, Westrup D, Müller M, Breddin H.K, Seifried E, Kirchmaier C.M. Platelet adhesion in patients with thrombasthenia Glanzmann, giant platelet throm-bocytopathy and storage pool disease on extracellular matrix. Thromb Haemostas 1997; Suppl: 67 (abstract PS269).
    PubMedGoogle Scholar
  • 13 Breddin H.K, Breddin H, Kirchmaier C.M, Keppler S. Methods to monitor the effects of GP IIb-IIIa -inhibitors and their interactions with other antithrombotic agents. Thromb Haemost 1995; 73: 1446 (abstract 2087).
    PubMedGoogle Scholar
  • 14 Hérault J.P, Peyrou V, Savi P, Bernât A, Herbert J.M. Effect of SR 12.1566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo. Thromb Haemost 1998; 79: 383-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Animar T, Scudder L.E, Coller B.S. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 1997; 4 (95) 614-7.
    PubMedGoogle Scholar
  • 16 Coller B.S, Lang D, Scudder L.E. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. Circulation. 1997; 95: 860-7.
    CrossrefPubMedGoogle Scholar